PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition
MP4•Episode home
Manage episode 416987448 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring perspectives from Dr Matthew D Galsky, including the following topics:
- HER2 alterations in urothelial cancer and current targeting approaches (0:00)
- Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
- Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
- Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
- Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
- Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
- Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)
1368 episodes
MP4•Episode home
Manage episode 416987448 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring perspectives from Dr Matthew D Galsky, including the following topics:
- HER2 alterations in urothelial cancer and current targeting approaches (0:00)
- Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
- Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
- Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
- Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
- Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
- Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)
1368 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.